Incidence and Prevalence of Glaucoma, Corticosteroid Response, and Ocular Hypertension in Uveitis and its Anatomical Subtypes.
Marshall Rayna F, Lee Daniel, Thorne Jennifer E, Kaleem Mona, Berkenstock Meghan K
AI Summary
This study found uveitic glaucoma incidence/prevalence decreased since 2013, but anterior and intermediate uveitis patients still face the highest risk, highlighting the need for vigilant monitoring in these groups.
Abstract
Purpose
Uveitic glaucoma represents one of the most serious, sight-threatening complications of ocular inflammatory disorders. In this study, we assessed the cumulative and yearly prevalence and incidence of uveitic glaucoma in the TriNetX United States (US) Collaborative Network, a database composed of over 100 million patient medical records.
Design
Incidence, Prevalence, and Trend study.
Participants
Subjects with uveitic glaucoma in the TriNetX database.
Methods
A retrospective study of a uveitic-glaucoma cohort, identified with patients having both ICD-10 codes of uveitis and glaucoma, ocular hypertension, or corticosteroid response diagnosed on the same day or after the onset of uveitis, was conducted using the TriNetX US database. Demographic information as well as cumulative and yearly incidence and prevalence of uveitic glaucoma were determined.
Main outcome measures
Cumulative and yearly incidence and prevalence of uveitic glaucoma, between 2013-2022. A sub-analysis of uveitic glaucoma by uveitis anatomic location was also conducted.
Results
30,681 patients with uveitic glaucoma were identified. The average age of the cohort at presentation was 67 years (SD = 19, 95% CI 66.8-67.2 years); 55.0% (n = 16 875, 95% CI 54.4-55.9%) were female and 50.7% (n = 15 555, 95% CI 50.1-51.3%) were Caucasian. Among the uveitis population, 15.5% of patients developed glaucoma in the 10-year time period (n = 30 681, 95% CI 15.3-15.6%). The cumulative incidence of uveitic glaucoma was 5 per 100 000 and the cumulative prevalence was 27 per 100,000 between 2013 and 2022. During the study period, the incidence and prevalence of uveitic glaucoma decreased. Patients with both anterior and intermediate uveitis (n = 529; 20.3%, 95% CI 18.8-21.9%) had the highest rates of uveitic glaucoma, followed by anterior (n = 20 849; 16.4%, 95% CI 16.2-16.7%), panuveitis (n = 48; 11.6%, 95% CI 8.5-14.7%), endophthalmitis (n = 273; 11.3%, 95% CI 10.9-11.7%), intermediate (n = 173; 10.0%, 95% CI 8.6-11.5%), and posterior (n = 1579; 8.2%, 95% CI 7.8-8.6%). Anterior and intermediate uveitis patients also had the highest rates of ocular hypertension (n = 465; 17.9%, 95% CI 16.4-19.3%) and corticosteroid response (n = 279; 10.7%, 95% CI 9.5-11.9%).
Conclusions
Since 2013, the incidence and prevalence rates of uveitic glaucoma have been decreasing. Patients with both anterior and intermediate uveitis patients had the highest relative rates of glaucoma compared to other uveitis subtypes.
MeSH Terms
Shields Classification
Key Concepts5
Among the uveitis population, 15.5% of patients (n = 30,681, 95% CI 15.3-15.6%) developed glaucoma in a 10-year period between 2013 and 2022.
The cumulative incidence of uveitic glaucoma was 5 per 100,000 and the cumulative prevalence was 27 per 100,000 between 2013 and 2022.
During the study period (2013-2022), the incidence and prevalence of uveitic glaucoma decreased.
Patients with both anterior and intermediate uveitis (n = 529; 20.3%, 95% CI 18.8-21.9%) had the highest rates of uveitic glaucoma, followed by anterior (n = 20,849; 16.4%, 95% CI 16.2-16.7%), panuveitis (n = 48; 11.6%, 95% CI 8.5-14.7%), endophthalmitis (n = 273; 11.3%, 95% CI 10.9-11.7%), intermediate (n = 173; 10.0%, 95% CI 8.6-11.5%), and posterior (n = 1579; 8.2%, 95% CI 7.8-8.6%) uveitis.
Anterior and intermediate uveitis patients also had the highest rates of ocular hypertension (n = 465; 17.9%, 95% CI 16.4-19.3%) and corticosteroid response (n = 279; 10.7%, 95% CI 9.5-11.9%).
Related Articles5
Ocular complications in children within 1 year after hematopoietic stem cell transplantation.
Cohort StudyPrevalence of ocular hypertension and glaucoma in patients with chronic ocular graft-versus-host disease.
Cohort StudyComment on: Incidence and prevalence of glaucoma, corticosteroid response, and ocular hypertension in uveitis and its anatomical subtypes.
LetterIncidence and Outcome of Uveitic Glaucoma in Eyes With Intermediate, Posterior, or Panuveitis Followed up to 10 Years After Randomization to Fluocinolone Acetonide Implant or Systemic Therapy.
Cohort StudyIncidence of secondary glaucoma in behcet disease.
Cohort StudyIs this article assigned to the wrong chapter(s)? Let us know.